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ABSTRACT
The Sox6 transcription factor plays critical roles in
various cell types, including erythroid cells.
Sox6-deficient mice are anemic due to impaired
red cell maturation and show inappropriate globin
gene expression in definitive erythrocytes. To
identify new Sox6 target genes in erythroid cells,
we used the known repressive double Sox6 consen-
sus within the ey-globin promoter to perform a
bioinformatic genome-wide search for similar, evo-
lutionarily conserved motifs located within genes
whose expression changes during erythropoiesis.
We found a highly conserved Sox6 consensus
within the Sox6 human gene promoter itself. This
sequence is bound by Sox6 in vitro and in vivo,
and mediates transcriptional repression in transient
transfections in human erythroleukemic K562 cells
and in primary erythroblasts. The binding of a
lentiviral transduced Sox6FLAG protein to the
endogenous Sox6 promoter is accompanied, in
erythroid cells, by strong downregulation of the
endogenous Sox6 transcript and by decreased
in vivo chromatin accessibility of this region to the
PstI restriction enzyme. These observations
suggest that the negative Sox6 autoregulation,
mediated by the double Sox6 binding site within its
own promoter, may be relevant to control the Sox6
transcriptional downregulation that we observe in
human erythroid cultures and in mouse bone
marrow cells in late erythroid maturation.
INTRODUCTION
Sox6 is a member of the Sox (Sry-type HMG box) family
of transcription factors, characterized by the presence of
an HMG domain that recognizes the minor groove on
DNA. The binding of Sox proteins to DNA forces it to
bend at about 75 , introducing local conformational
changes. The ability of Sox proteins to bind in close
proximity to other transcription factors and to distort
DNA suggests that they can act as ‘architectural
proteins’, possibly by promoting the assembly of bio-
logically active multiprotein complexes. These complexes,
in turn, mediate the interactions between distant chroma-
tin domains, bringing together promoter/enhancer
regions, ﬁnally assembling the ‘chromatin hubs’ that
control gene expression regulation. Within this general
frame, Sox6 has been suggested to act both as activator
or repressor, depending on its interactions and on its
target sequences (1–3). The Sox domain recognizes a
very degenerate (A/T)(A/T)CAA(A/T)G consensus,
making it very difﬁcult to identify its in vivo targets:
the best-characterized and validated Sox6 target
sequence on the regulatory elements of the chondrocyte
gene Col2a1 is, for example, composed of four sites each
having different mismatches relative to the HMG box
consensus (4). Moreover, the presence of adjacent pairs
of Sox sites on different known targets suggests that
double Sox sites might likely be the preferred Sox6
targets, although the relative arrangement and
orientation of the two sites is not yet clearly deﬁned
(1–3 and references therein).
Murine Sox6 null mutants (p100H) show delayed
growth, myopathy, arterioventricular heart block and
die within 2weeks following birth (5). Sox6 is indeed
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(5,6,7), cartilage (4,8) and cardiac and skeletal muscle
(9,10). Recent reports indicate that complete Sox6
ablation causes a perturbation of erythropoiesis resulting
in the presence of increased numbers of nucleated and
misshaped red cells in the fetal circulation and in a
strong relative increase of embryonic (ey) globin gene
expression (11–13). In particular, Sox6 directly silences
ey-globin expression in murine deﬁnitive erythropoiesis
by binding to a double Sox6 site lying within a 36-bp
region on the ey proximal promoter (13). Moreover,
embryonic liver stem cells from Sox6 null mice engrafted
into lethally irradiated wild-type (WT) adult mice, show
levels of ey expression in the spleen and bone marrow that
are higher than those observed in control mice trans-
planted with wild type cells (12). Finally, Sox6 cooperates
with BCL11a to downregulate the g-globin gene in adult
erythroid cells (14).
The emerging critical role of Sox6 in erythropoiesis
prompted us to search for new direct targets by combining
a bioinformatic approach with DNA microarray analysis.
Among the resulting candidate Sox6 binding sites, we
found an evolutionarily conserved double Sox6 site lying
within the Sox6 proximal promoter itself, and we
demonstrated that Sox6 binds to this region repressing
its transcriptional activity in K562 cells. Accordingly,
overexpression of an exogenous Sox6 by lentiviral
transduction in both K562 cells and primary human
erythroblast represses the endogenous Sox6 transcript
expression. To link this observation to the Sox6 expression
proﬁle during human erythropoiesis, we used as model
system primary CD34
+ cells (from both Cord Blood and
Peripheral Blood) undergoing in vitro erythroid differenti-
ation. In both cultures, Sox6 expression peaks in early
erythroblasts and decreases along with erythroid differen-
tiation. Together, these data suggest that the Sox6
autoregulation mediated by the double Sox6 binding
site within the promoter may be relevant for
Sox6 downregulation in the ﬁnal stages of erythroid
differentiation.
MATERIALS AND METHODS
Cell cultures
CD34
+ cells were immunopuriﬁed from Human Cord
Blood (HCB), cultured for 2weeks in StemSpan (Stem
Cell Technologies) containing 20% of fetal bovine serum
(FBS, Hyclone) and supplemented with 10ng/ml of
human stem cell factor (hSCF), 1U/ml of human erythro-
poietin (EPO), 1ng/ml of human interleukin-3 (hIL-3),
10
 6M dexamethasone (Sigma) and 10
 6M b-estradiol
(Sigma) (15). CD34
+ cells were seeded at a concentration
of 10
5cells/ml and diluted over time to maintain the
cell concentration in the range of 1–2 10
6cells/ml.
Cells were collected and analysed on days 6, 8, 10,
12 and 14.
CD34
+cells from human peripheral adult blood (HPB)
were immunopuriﬁed after buffy coat isolation and eryth-
roid cultures were done as detailed in ref. (16): cells were
cultured at a density of 10
5cells/ml in alpha-minimal
essential medium in the presence of SCF, IL-3 and Epo.
Cyclosporine A at 1mg/ml was added to inhibit lympho-
cyte and monocyte growth. After 7days of culture, cells
were replated in erythroid differentiation medium. Cell
samples were collected and analysed on days 7 and 14.
For both cultures, erythroid differentiation was monitored
by FACS analysis for the expression of GlycophorinA
(CD235), and by cell-morphology analysis on
cytocentrifuged samples stained with May–Grunwald–
Giemsa. Primary human cells were obtained according
to Institutional guidelines. K562 cells were cultured in
RPMI medium supplemented by 10% FBS, PenStrep
and L-glutamine.
Electrophoretic mobility shift assay (EMSA)
DNA oligonucleotide probes were labeled at the same
speciﬁc activity: 3pmol of each double-stranded oligo-
nucleotide were labeled with g-
32P ATP by using T4
Polynucleotide Kinase (NEB) and puriﬁed on 8% acryl-
amide gel. Labeled probe at 30fmol was incubated with
10mg of nuclear or total extracts, for 20min at 15 Ci na
buffer containing 5% glycerol, 50mM NaCl, 20mM Tris,
pH 7.9, 0.5mM EDTA, 5mM MgCl, 1mM dithiothreitol
(DTT), 500ng/ml poly(dG-dC) and 50ng/ml bovine serum
albumin (BSA) in a 15-ml ﬁnal reaction mixture.
The reaction mixture was then loaded onto a 8% poly-
acrylamide gel (29:1 acrylamide-bisacrylamide ratio) and
run at 4 C and 150V for 3h. Nuclear extracts were
prepared according to standard protocols (17,18). The
antibodies used for the supershift analysis were:
anti-FLAG, (Sigma F7425); anti-GATA1 (SantaCruz
N6, sc-265).
Competitions were done using a 25-, 50- and 100-fold
molar excess (with respect to the radiolabeled probe) of
‘cold’ oligonucleotides.
Oligonucleotide probes:
WT probe: Fw: 50-CCTCTGTAACAAAGTTTCTTTGT
TTTAATGG-30,
Rev: 50-CCATTAAAACAAAGAAACTTTGTTACAG
AGG-30;
Mut probe: Fw: 50-CCTCTGTGGCAGAGTGTCTGTG
TGTGAATGG-3,
Rev: 50-CCATTCACACACAGACACTCTGCCACAG
AGG-30;
Mut1 probe: Fw: 50-CCTCTGTGGCAGAGTGTCTTT
GTTTTAATGG-30,
Rev: 50-CCATTAAAACAAAGACACTCTGCCACAG
AGG-30;
Mut2 probe: Fw: 50-CCTCTGTAACAAAGTGTCTGT
GTGTGAATGG-30,
Rev 50-CCATTCACACACAGACACTTTGTTACAGA
GG-30.
Sox6 overexpression vectors
The Sox6 murine cDNA (19) was kindly provided by Prof.
Michiko Hamada-Kanazawa, Kobe-Gakuin University,
Japan. The Sox6 cDNA was transferred into the
pCMV-Tag 4B plasmid (Stratagene), in frame with a 30
FLAG epitope, (EcoRI-EcoRV restriction sites), to
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fection assays. The Sox6 recombinant protein lacks the 49
C-terminal aminoacids: this shorter molecule fully retains
Sox6 biological proprieties (19) and allows discrimination
between endogenous and exogenous Sox6. The
Sox6FLAG cassette (EcoRI-KpnI) was blunted and
cloned immediately upstream to the IRES-Emerald GFP
cassette into the blunted BamHI site of the pHR SIN BX
IR/EMW [derived from pHR SIN CSGW, (20)] lentiviral
vector. The two packaging plasmids psPAX2 and pMD-
VSVG were used to produce Lentiviral pseudo-particles in
293T cells (www.lentiweb.com).
The expression levels of exogenous Sox6FLAG versus
the endogenous transcript was estimated in K562 cells and
in cultures of primary Cord Blood-derived cells (at Day
10, peak of Sox6 expression) by Real Time PCR, using
GAPDH mRNA as a standard for comparison
(Supplementary Figure S1).
Lentiviral harvesting protocol
Exponentially growing HEK 293T cells were transfected
using Lipofectamine 2000 (Invitrogen) with the three
vectors lentiviral system. Nearly 48h after transfection,
the supernatant containing recombinant viruses was har-
vested, ﬁltered (0.45mm), centrifuged at 20.000g for 8h
and then frozen at  80 C. Lentiviruses were titrated on
HEK 293T cells by measuring the percentage of GFP
positive cells by FACS analysis.
Luciferase reporter plasmids
The human Sox6 promoter region from nt  1116 to  1
was obtained by direct ampliﬁcation from genomic DNA
with Phusion High-ﬁdelity DNA Polymerase (Finnzymes)
using the following primers:
Fw: 50-ATCGGTACCGGGCTGAGTTAGATATTTAT
TTC-30;
Rev: 50-ATCTCGAGAGATCTGAATTCATGAAAGT
GACCTG-30
containing a KpnI and XhoI restriction site (underlined),
respectively, for further cloning into the corresponding
sites of the pGL2 luciferase reporter vector (Promega).
To generate the corresponding plasmid mutated in the
Sox6 consensus ( 1116Mut) a two-step PCR approach
was used: (i) in the ﬁrst series of PCRs, mutations were
introduced by amplifying the wild-type template sequence
combining the above Fw and Rev primers with the
following oligonucleotides, carrying the desired
mutations:
RevMut 50-GGCAGAGTGTCTGTGTGTGAATGGAA
CTAAAAATATGCTG-30
FwMut 50-CACACACAGACACTCTGCCACAGAGG
CTGTATTCTTTC-30.
(ii) The two ampliﬁed fragments were gel puriﬁed,
annealed and used as a template for a second round of
PCR with the external Fw and Rev primers. The resulting
mutated fragment was cloned (KpnI-XhoI sites) into
pGL3.
The DNA region of 234nt (from nt  991 to  759)
containing the double Sox6 site, was ampliﬁed with the
following primers:
Fw: 50-ACGTGGTACCGATCCATTGTTTTTCAGA
AGG-30
Rev: 50-ACGTCTCGAGAACAAAGAAACTTTGTTA
CAGAGGC-30
containing the KpnI and XhoI sites, as above, for cloning
into the pGL2 luciferase reporter vector (Promega),
upstream to the minimal Gata-1 promoter and to the
Gata-1 erythroid-speciﬁc enhancer region HS2 (16). To
mutate the double Sox consensus, the same region was
ampliﬁed with a Reverse primer containing the same
mutations proved to abolish Sox6 binding in EMSA
assay:
Rev: 50-ACGTCTCGAGCACACAGACACTCTGCCA
CAGAGGC-30.
All the ampliﬁed DNA regions were sequenced to avoid
undesired mutations.
Transfection experiments
1 10
5 Exponentially growing K562 cells, seeded in
24-well dishes, were transfected in 0.5ml of Opti-MEM
medium (Invitrogen), using 2ml of Lipofectamine 2000
(Invitrogen), 800ng of the reporter plasmid and increasing
amounts (indicated in the ﬁgures) of the Sox6 expression
plasmid (pCMV-Sox6Tag4B) per well. The pCMV-Tag4B
empty vector was added to each transfection at the con-
centration required to equalize the total amount of DNA
transfected in each reaction. After 24h, total cellular
extracts were prepared and Luciferase activity was
measured according to the Promega Luciferase reporter
system protocol. P19 cells were transfected in the same
condition in a 12-well dish. Retinoic acid (RA) at
500nM was used to induce Sox6 expression (19). All ex-
periments were repeated in quadruplicate with at least two
independent plasmid preparations.
Transfection of primary erythroblasts was obtained by
nucleofection (Human CD34
+ cell Nucleofector Kit,
Amaxa VPA-1003) of 5mg of the Luciferase reporter con-
structs together with 50ng of Renilla reporter plasmid to
normalize for transfection efﬁciency. Each transfection
was carried out in triplicate and two independent
cultures were used from both peripheral and cord blood.
Chromatin immunoprecipitation assay
Brieﬂy, K562, FACS-sorted mouse bone marrow cells or
human primary erythroblasts (1–2 10
6 cells for each
immunoprecipitation reaction) were ﬁxed with 0.4% for-
maldehyde for 10min at room temperature, and
chromatin was sonicated to a size of  500nt.
Immunoprecipitation was performed after overnight incu-
bation and subsequent incubation with protein A agarose
(Upstate biotechnology). The following antibodies were
used: anti-FLAG antibody (Sigma F-7425), anti-Sox6
antibody (Millipore Ab5805), anti-H3K4me1 (Abcam
8895-100) and anti-H3K27me3 (Upstate 07-449),
488 Nucleic Acids Research, 2011,Vol. 39,No. 2anti-HDAC1 (Millipore 17-608). Immunoprecipitated
DNA was then analysed by amplifying an equivalent of
10
4 cells DNA with the following oligonucleotides:
Sox6 promoter: Fw 50-TTTGAAAGAATACAGCCT
CTG-30,
Rev 50-ATGCATTAAGGTGGTTTGGTA-30;
GAPDH locus: Fw 50-CGGAGTCAACGGATTTGGTC
GTAT-30,
Rev 50-AGCCTTCTCCATGGTGGTGAAGAC-30;
Sox4 locus: Fw 50-CATGGTGCAGCAAACCAACA-30,
Rev 50-TTCATGGGTCGCTTGATGTG-30;
Cyclin D1 promoter: Fw 50-CTCCCGCTCCCATTCTC
T-30, Rev 50-GAGGCTCCAGGACTTTGC-30.
Mouse Sox6 promoter: Fw50-GCATTAGAAAGTAGTT
AGGTCG, Rev50-CAGCCTCTGTAACAAAGTTCC;
Mouse Sox6 exon16: Fw50-TGCGACAGTTCTTCACT
GTGG, Rev 50-CGTCCATCTTCATACCATACG.
Immunoprecipitation was repeated three times on
independent chromatin preparations.
RNA isolation and RT–PCR
Total RNA from 10
5 cells (both K562 or differentiating
human CD34
+ cells at the different time points) was
puriﬁed with TRI Reagent (Applied Biosystem
AM9738). Before cDNA synthesis, RNA was treated
with RQ1 DNase (Promega) for 30min at 37 C. cDNA
was prepared using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystem cat n 4368814)
and then diluted 1:50 for ampliﬁcation. Negative control
reactions (without reverse transcriptase) gave no signal.
Real-time analysis was performed using ABI Prism 7500,
(PE Applied Biosystems).
Primers were designed to amplify 100 to 150-bp
amplicons and were based on sequences from the
Ensembl database (http://www.ensembl.org/Homo_
sapiens/Info/Index). Samples from three or more inde-
pendent experiments were analyzed in triplicate. Speciﬁc
PCR product accumulation was monitored by SYBR
Green dye ﬂuorescence in 25-ml reaction volume.
Dissociation curves conﬁrmed the homogeneity of PCR
products.
The same forward primer was used to amplify both
endogenous and exogenous Sox6 cDNA:
Fw: 50-GAGGCAGTTCTTTACTGTGG-30. To dis-
criminate between endogenous and transduced RNA
variants, two different reverse primers were used: Rev1:
50-CCGCCATCTGTCTTCATAC-30 complementary to
the extreme 30 of Sox6 transcript and Rev2. 50-CTTATC
GTCGTCATCCTTGTA-30, which matches with the
FLAG coding region (the combination of primers (F,
R1 and R2) is schematized in Figure 6A). Primers for
GAPDH were: Fw: 50-ACGGATTTGGTCGTATTG
GG-30, Rev: 50-TGATTTTGGAGGGATCTCGC-30;
Mouse Sox6 primers: Fw: 50-TGCGACAGTTCTTCAC
TGTGG-30, Rev: 50-CGTCCATCTTCATACCAT
ACG-30; Mouse HPRT primers: Fw: 50-CCTGCTGGAT
TACATTAAAGCACTG-30, Rev: 50-GTCAAGGGCAT
ATCCAACAACAAAC-30.
Western blot
K562 total and nuclear extracts were prepared according
to standard protocol (17,18) and proteins were subjected
to SDS–PAGE separation and blotting. The endogenous
Sox6 protein was detected by the anti Sox6 (c-20) Santa
Cruz sc-17332 antibody raised against the 20aa C-terminal
epitope (absent in the exogenous Sox6FLAG protein).
The Sox6FLAG and Sox4FLAG proteins were detected
by the use of the anti-FLAG antibody Sigma F7425.
Protein loading was checked by reprobing ﬁlters with a
monoclonal anti hnRNP-C1/C2 antibody (Sigma
R5028). Antibodies binding was detected by using appro-
priate horseradish peroxidise-conjugated IgG and
revealed by ECL (LiteAblot, Euroclone).
Cell sorting
Freshly extracted mouse bone marrow cells were
disaggregated in phosphate-buffered saline, and incubated
with the following labeled antibodies: allophycocyanin
(APC) anti-mouse CD117 (c-Kit); PE anti-mouse CD71,
and FITC anti-mouse TER119, all from Becton
Dickinson, RD. The sorting was performed by a MoFlo
(DAKO-Cytomation) cell sorter and purity of the
obtained cells populations was >95%.
Restriction enzyme accessibility assay
PstI chromatin accessibility assay was performed as pre-
viously described (21). Brieﬂy, nuclei were collected from
2 10
6 Sox6- or empty vector-transduced K562 cells 72h
post infection, using RSB buffer (10mM Tris–HCl, pH
7.5, 10mM NaCl and 3mM MgCl2) containing 0.2%(v/
v) NP40 and 10mM DTT. Nuclei were washed in RSB
buffer without NP40 and resuspended in NEB Buffer
3 (100mM NaCl, 50mM Tris–HCl, 10mM MgCl2,
1mM dithiothreitol, pH 7.9) and aliquots were incubated
at 37 C for 15min with or without 30units of PstI (NEB).
Digestions were stopped adding the same volume of STOP
Buffer (0.6M NaCl, 20mM Tris–HCl pH 8, 10mM
EDTA, 1% SDS). Samples were then treated overnight
with proteinase K and DNA was recovered after phenol/
chloroform extraction and subsequent ethanol
precipitation.
Digested DNA was quantiﬁed by Real Time PCR (ABI
Prism 7500, PE Applied Biosystem Real Time PCR
system) as described in (22). A PstI non-containing
amplicon (within 18S ribosomal subunit gene) was used
as internal control to normalize for DNA loading.
Primers:
GATA Promoter Fw: 50-CTCCCGCCAGCACTGGCC
TG-30
GATA Promoter Rw: 50-GCCGGTGTGGGCTAGACT
CC-30
Sox6 Promoter Fw: 50-CAAGATCCATTGTTTTTCAG
AAGG-30
Sox6 Promoter Rw: 50-AACAAAGAAACTTTGTTACA
GAGGC-30
18S Fw: 50-TTTCGGAACTGAGGCCATGATTAAG-30
18S Rw: 50-AGTTTCAGCTTTGCAACCATACTCC-30
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Sox6 expression during erythroid maturation
To get insight into the regulation of the Sox6 gene during
erythropoiesis, we analyzed the Sox6 expression proﬁle in
different cellular models of erythroid differentiation.
To this end, we used primary human erythroid liquid
cultures from CD34
+ cells puriﬁed either from adult per-
ipheral [HPB; (16)], or umbilical cord blood [HCB; (15)],
widely considered a physiological model of human
erythropoietic differentiation. In these cultures, puriﬁed
CD34
+ cells are ampliﬁed to erythroblasts and then
induced to terminal differentiation in a semi-synchronous
way into mature erythrocytes. In HCB-derived cultures,
Sox6 expression was analyzed by RT–PCR at Day 0
(puriﬁed CD34
+ cells), during erythroblast ampliﬁcation
(Day6), at the end of the erythroid precursors ampliﬁca-
tion stage (Day 8) and then at days 10, 12 and 14 during
erythroid induced differentiation. As shown in Figure 1A,
Sox6 expression is absent in CD34
+ cells, starts to be de-
tectable at Day 8 (72% of glycophorinA positive (GpA
+)
cells, as estimated by FACS analysis, not shown), reaches
a peak around day 12 (85% of GpA
+ cells), to ﬁnally
decrease at Day 14, corresponding to the end of the
culture and to the maximum extent of erythroid differen-
tiation ( 90% of GpA
+ cells).
Sox6 expression shows a similar pattern in the
two-phase erythroid culture from CD34
+ cells puriﬁed
from adult HPB (Figure 1B): Sox6 mRNA is absent in
puriﬁed CD34
+ cells (Day 0), accumulates at the end of
the erythroblasts ampliﬁcation stage (Day 7, correspond-
ing to 67% of GpA
+cells) and then decreases at Day 14 of
the culture, when erythroid differentiation is completed
(97% of GpA
+ cells).
We then analyzed Sox6 expression in vivo, in mouse
bone marrow FACS-sorted cell populations repre-
senting progressive stages of erythroid maturation.
As shown in Figure 1D, Sox6 is modestly expressed
in the more immature (Kit
+CD71
 ) cell population,
increases together with erythroid differentiation
(CD71
highTer119
low and CD71
highTer119
high cells) and
then falls in the most mature cells (CD71
lowTER119
high).
These latter data conﬁrm, in an in vivo system, the
observation, made in the ex vivo primary cultures that,
during mouse and man erythoid differentiation, Sox6
expression peaks during early erythroid differentiation,
but then decreases at later stages.
Finally, we examined Sox6 expression in a widely used
cell line, the erythroleukemic K562 cells. These cells
express low levels of Sox6 that remain unchanged upon
addition of hemin, a drug that induces a substantial degree
of differentiation in these cells (Figure 1C).
Identiﬁcation of Sox6 targets on DNA
Sox proteins share a conserved DNA-binding HMG
box domain, which dictates their preference for the recog-
nition of the hexameric core sequence 50-WWCAAW-30
(W=A/T) (3).
The only Sox6 target deﬁned so far in erythropoietic
cells is the double Sox6 binding site within the mouse
ey-globin proximal promoter. This sequence, consisting
of two AACAA(A/T)G sites in opposite orientation,
spaced by 8nt, is thought to concur to the ey-globin
gene repression in adult erythroid cells (13) (Figure 2A).
To identify new Sox6 target genes in erythroid cells, we
performed an in-silico genome-wide search using the web
free tool TFBScluster (http://hscl.cimr.cam.ac
.uk/TFBScluster), which allows identiﬁcation of patterns
of binding sites present in evolutionarily conserved regu-
latory regions (23).
By taking as a model the double Sox6 binding site from
the "y-globin promoter, we set TFBScluster in order to
search for two 50-WWCAAW-30 sites within a cluster of
30nt. This search found 875 consensus sequences in
mouse/man conserved regions, interspersed in the human
genome (Figure 2B). Only a minority of them (6%) were
found near the transcription start site of known genes,
while the others were located in introns (56%), or down-
stream to the 30-end of known genes (38%). In principle,
every single identiﬁed target could be relevant, but to
narrow the search to regions of high regulatory potential
and to the erythroid system, we matched the 56 consensi
found within 10-kb upstream to known genes with a list of
differentially expressed genes (DEG) at different stages of
erythroid maturation in mouse deﬁnitive erythropoiesis.
This DEGs list (C.C., A.R. unpublished data) results
from a DNA microarray analysis on three populations
of hematopoietic cells puriﬁed by FACS sorting from
E13.5 fetal livers, according to their relative expression
of c-Kit (that marks early progenitor cells), and Ter119
(a protein associated to GlycophorinA, expressed only by
erythroid committed cells). These populations were:
cKit
+/TER119
  cells, representing pluripotent hemato-
poietic progenitors; cKit
+/TER119
+ cells, corresponding
to erythroid committed early progenitors and cKit
 /
TER119
+ +cells consisting of more differentiated erythro-
blasts and mature erythrocytes.
Among the seven genes identiﬁed by the merging of
these two lists (see Figure 2D), there is Sox6 itself, sug-
gesting a potential direct transcriptional auto-regulation.
The position and the evolutionary conservation of this
double Sox6 consensus was also conﬁrmed by the use of
two additional bioinformatics tools: the USCS database
(http://genome.ucsc.edu/) and the TESS Transcription
Element Search System software (http://www.cbil.upenn
.edu/cgi-bin/tess/tess).
The Sox6 promoter contains a highly conserved double
Sox6 consensus
The evolutionarily conserved putative double Sox6
binding site maps within a mouse/man homology region,
extending from nt+1 [transcriptional start site, mapped in
(24)] to  1116, in position  775/ 759; Figure 3A and B.
This site lies in a block of 31 conserved nucleotides, and is
composed of two single sites in opposite orientation,
spaced by three bases. The two Sox6 consensus binding
sites are fully conserved from chicken to man whereas few
substitutions are present within the spacing nucleotides
(Figure 3C).
490 Nucleic Acids Research, 2011,Vol. 39,No. 2To assess the ability of the mouse/man conserved region
(+1/ 1116) to promote transcription in an erythroid
context, we cloned it immediately upstream to the
Luciferase reporter gene. This region (1116-S6), when
compared with the promoterless pGL3 background
plasmid and with the Thymidine kinase promoter (pTK),
shows an intermediate transcriptional activity. This
suggests that, although additional enhancer sequences
Figure 1. Sox 6 expression during erythroid maturation. (A) Erythroid liquid cultures from CD34
+ cells puriﬁed from HCB. Day 0: puriﬁed CD34
+
cells; Day 8: beginning of the erythroid differentiation phase. Day 14: end of the culture, when 90% of cells are GpA
+.( B) Erythroid liquid cultures
from CD34
+ cells puriﬁed from HPB. Day 0: puriﬁed CD34
+ cells; Day 7: beginning of erythroid differentiation; Day 14: end of erythroid
differentiation (97% GpA
+cells) (C) Semi-quantitative RT–PCR on cDNA from K562 cells, treated (+) or not ( ) with hemin (50mM for
4 days). PCR ampliﬁcation cycles are indicated below the lanes. (D) Mouse Bone Marrow cells sorted according to their erythroid maturation,
from more immature kit
+CD71
  to progressively more mature stages CD71
highTer119
low, CD71
highTer119
high, CD71
low Ter119
high. Semi-quantitative
(left) and RealTime (right) PCRs were performed on cDNA from cells indicated in the ﬁgures. The Sox6 expression level is normalized on GAPDH
(human cells) and HPRT (mouse cells), respectively.
Nucleic AcidsResearch, 2011, Vol.39,No. 2 491may be required for Sox6 optimal activity in K562, this
element behaves as a promoter in an erythroid context
(Figure 3D).
Sox6 binds to the putative double consensus identiﬁed
within the Sox6 promoter
To test the ability of Sox6 to bind to the above identiﬁed
consensus, we set up EMSA experiments using as a probe
either an oligonucleotide encompassing the double Sox6
consensus site (WT) or the corresponding oligonucleotides
mutated in only one (Mut1 and Mut2) or in both Sox6
binding sites (MUT; Figure 4A). As shown in Figure 4B
the WT probe, when incubated with K562 nuclear
extracts, gives a weak but consistent retarded band (lane
1), which becomes barely detectable when a similar
amount of total protein extracts is used (lane 7).
To overcome the low level of SOX6 in K562, we moved
to protein extracts from K562 cells transfected with a
pCMV-Sox6FLAG expressing vector. When these
extracts are used, a stronger band, in the same position
of that generated by the endogenous Sox6, is observed in
both nuclear (lane 2) and total (lane 8) extracts. This band
is speciﬁcally supershifted by increasing amounts of the
anti-FLAG antibody (lanes 3–4 and 9), but it is not
altered by the addition of the unrelated anti-GATA-1
antibody (lanes 5–6).
When tested in the same conditions, the probe mutated
in both Sox6 binding sites (MUT) fails to give any
retarded band, conﬁrming that the above described band
is speciﬁcally due to Sox6 binding to the double consensus
binding site (Figure 4B; lanes 10–18).
To further conﬁrm the speciﬁcity of Sox6 binding to the
double consensus lying within its own promoter, we set up
competition experiments with an oligonucleotide corres-
ponding to a published Sox6 consensus located in the
regulatory regions of the cartilage-speciﬁc gene Col2a1
(4). As shown in Figure 4C, the Col2a1 unlabeled probe
efﬁciently competes for the Sox6 band (lanes 3–5). When
the two oligonucleotides mutated in the single Sox6
binding sites (Mut 1 and Mut 2 in Figure 4A) are used
as cold competitors, both oligonucleotides compete for the
Sox6 band with a decreased afﬁnity (lanes 6–11) if
compared with the Col2a1 probe (lanes 3–5), and with
the unlabelled WT probe (lane 2). Direct binding on
the Mut1- and Mut2-labeled probes conﬁrms the
reduced ability of these oligonucleotides to bind Sox6
(Figure 3C; compare lanes 15–17). Taken together these
data suggest that both single Sox6 binding sites contribute
to the overall Sox6 binding observed with the WT probe.
The  775 Sox6 binding sites within the Sox6 promoter
mediate transcriptional repression in K562 cells
To test the functional role of the  775/ 759 Sox6 binding
sites, we prepared a series of Luciferase reporter con-
structs that we assayed by transient transfection experi-
ments in K562 cells. Each experiment was done with at
least two independent DNA plasmid preparations, each of
them transfected at least in triplicate.
We ﬁrst introduced within the 1116-S6 construct
described above the same point mutations previously
shown to completely abolish Sox6 binding in EMSA
(Figure 4A) and we compared the response of the resulting
WT and Mut plasmids (1116-S6wt and 1116-S6mut;
Figure 5A) to increasing amount of Sox6 in cotransfection
experiments in K562 cells. When cotransfected, Sox6 has a
general activation effect on several promoters
(Supplementary Figure S2; including 1116-S6). Taking
this into account, the ratio between the activation of the
Figure 2. Schematic representation of the bioinformatic strategy used to
identify new direct Sox6 targets. (A) Sequence of the double Sox6 binding
site located within the mouse ey-globin promoter. Nucleotides positions
are indicated on top of the sequence. Search criteria set in TFBScluster
search are indicated. (B) TFBScluster search output. The identiﬁed
potential Sox6 binding sites are clustered on the basis of their relative
position with respect to known genes. The absolute number—and the
corresponding percentages—of sites for each group is reported in the
pie-chart. (C) The merge of the list of the 56 potential Sox6 binding sites
located within 10Kb upstream to known genes with the list of genes
differentially expressed during mouse erythropoiesis identiﬁed seven
erythroid genes potentially regulated by Sox6 (listed in D). For each
potential target site (including the one within the Sox6 locus itself) the
distance from the transcriptional start site, the exact Sox consensus
sequence, and the evolutionary conservation are indicated.
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of increasing amount of Sox6 (Figure 5B), suggesting a
repressive role of Sox6 on the double Sox6 sequence.
To rule out the possibility that this effect might be
due to non-physiological Sox6 concentrations in
contransfected cells, we transfected the same constructs
in P19 cells grown in the presence or in the absence of
RA. Under RA induction, P19 cells accumulate Sox6
(as shown by RT–PCR, right panel), an event which
preludes to their differentiation toward the neuronal
lineage. As shown in Figure 5B the two
constructs (1116-S6wt and 1116-S6mut) behave as in
K562, conﬁrming that the Sox6 double consensus
mediates transcriptional repression in two independent
cell contexts (K562 and P19 cells) in which Sox6 is
actively transcribed.
Figure 3. Fine mapping of the double Sox6 binding site on the human Sox6 promoter. (A) Schematic representation of the 50-region of the human
Sox6 locus on chromosome 11. The thick arrows indicate the position of the double Sox6 binding site, located within the region immediately
upstream the main transcript start site. Note that the transcription orientation is from right to left. (B) UCSC genome browser (http://genome.ucsc
.edu/) graphical map of the human Sox6 promoter region. The thick arrows indicate the same Sox6 binding sites as in A. The  1116nt promoter
region studied in transfection experiments is indicated with a dotted line under the panel. (C) Nucleotide conservation of the region ( 775/ 759)
containing the two Sox6 binding sites (black arrows). The few substitutions in the spacer region between the two single sites are underlined. (D) The
 1116nt conserved region behaves as a promoter in K562 cells. The constructs used are schematically represented on the left of the ﬁgure. Luciferase
activity is given in arbitrary units, standard deviations are represented on the top of each column.
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(1116-S6wt and 1116-S6mut) was also tested in primary
erythroblasts differentiated from CD34
+ cells puriﬁed
from both peripheral and cord blood (Figure 5C).
In these experiments cells were nucleofected at two time
points, corresponding to the onset (Day 8) and to the
maximum (Day 12) of Sox6 expression, respectively (as
assayed by Real Time PCR, upper panels; see also
Figure 1), and analyzed 24h after transfection. Under
these conditions, the 1116-S6wt construct (middle
panels) is downregulated at Day 12 in correspondence of
the Sox6 increase; in contrast, the activity of the
1116-S6mut construct, although slightly lower than that
of the WT construct at Day 8, is not signiﬁcantly modiﬁed
between Day 8 and Day 12 (lower panels). By combining
the data obtained with both the peripheral and cord blood
cultures (Figure 5D), the mutated construct results to be
signiﬁcantly more active (P<0.03) at late phases of
differentiation (Day 12). This repression is associated to
direct in vivo binding of SOX6 to its own promoter, as
demonstrated by immunoprecipitation of chromatin
from cells at the same Day 12 with an anti-Sox6
antibody (Figure 5E), further suggesting that the binding
of SOX6 to this element contributes to the repression
of Sox6 transcription when Sox6 expression reaches
high levels.
Finally, to test whether this element is able to mediate
transcriptional repression when transferred to an heterol-
ogous, highly active transcriptional context, we restricted
the Sox6 50-ﬂanking region described earlier (the 1116nt,
Figure 3) to 234nt containing this site and we cloned it
upstream to a strong erythroid-speciﬁc regulatory cassette
(consisting of the core of the HS2 Gata-1 enhancer linked
to the 330nt Gata-1 minimal promoter, (16, pe+WT).
We also made a similar construct (pe+MUT) in which
the double Sox6 site is mutated as above (Figure 5F).
These constructs were cotransfected in K562 cells
together with increasing amounts of the pCMV
Sox6FLAG overexpressing plasmid.
As shown in Figure 5G, the pe+WT plasmid is progres-
sively repressed in a dose dependent manner by the sim-
ultaneous cotransfection of increasing amounts of
the Sox6 expressing vector (7, 11, 15 dark columns).
On the other hand, the corresponding pe+MUT construct,
mutated in the Sox6 consensus (columns 8, 12, 16) is
insensitive to Sox6 repression. Moreover, the effect of
Sox6 on the double Sox6 binding site is highly speciﬁc,
since the cotransfection of a similar Sox4 overexpressing
plasmid (at the highest concentration used for Sox6) fails
to modify the activity of the pe+WT reporter (column 19).
The amount of Sox6 and Sox4 produced by the two
plasmids is similar, as shown by the western blot on the
right panel.
Figure 4. Sox6 binds with high afﬁnity to the  775/ 759 double con-
sensus on human Sox6 promoter. (A) Nucleotide sequence of the four
probes used in EMSA experiments. The two Sox6 sites are underlined
and the mutations destroying the Sox6 consensus are marked by aster-
isks. (B) EMSA experiments: probes in panel A were
32P labeled and
incubated with either nuclear (lanes 1–6 and 10–16) or total K562 cell
extracts (lanes 7–9 and 16–18). Extracts from K562 cells transfected
with the pCMV-Sox6FLAG expressing vector: black bars over lane
numbers; increasing amounts of antibodies are indicated as + and
+ +, respectively.
32P labelled probes are indicated below the panel.
The retarded band produced by Sox6 binding is indicated by the grey
arrow: its speciﬁcity is demonstrated by the use of a speciﬁc anti-FLAG
antibody (lanes 3 and 4). The MUT probe, mutated in both Sox6
consensus sites, fails to give any retarded band when tested in the
same conditions as for the wild-type (WT) probe (lane 10–18).
(C) Unlabeled competitor oligonucleotides (sequences in panel A)
were added at three increasing concentrations and are indicated on
top of the panel. WT: lane 2 (at the intermediate concentration).
Col2a1-derived Sox6 consensus site (ref. 4): lanes 3–5. Mut1: lanes
6–8. Mut2: lanes 9–11 MUT: lanes 12–14.). Right panel: direct
binding of the WT and Mutated probes.
494 Nucleic Acids Research, 2011,Vol. 39,No. 2Figure 5. Sox6 represses its own promoter in cotransfection experiments in K562 cells. (A) The  1116/ 1 region, either WT or mutated in the Sox6
consensus was cloned upstream to the Luciferase reporter gene. The mutations in the Sox6 consensus are the same as in Figure 4A, shown to abolish
Sox6 binding in EMSA. (B) The two constructs were transfected either in K562 cells (left panel) with increasing doses of a Sox6 expressing plasmid,
or in P19 cells (right panel) induced or not with RA. RA treatment induces Sox6 in P19 cells as shown by RT–PCR (right panel). In both cell lines,
Sox6 induces a repression of the WT construct when compared to the mutated one. Statistical analyses are indicated above the chart. (C) Primary
Continued
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exogenously overexpressed Sox6
Since increasing amounts of Sox6 downregulate the Sox6
double consensus-Luciferase reporter construct (pe+WT;
Figure 5), we wished to conﬁrm the effect of Sox6
overexpression on the endogenous Sox6 gene transcrip-
tion, by overexpressing in K562 cells a Sox6 protein that
could be distinguished from the endogenous Sox6. To this
end, we cloned a Sox6 cDNA lacking the 30 147nt, in
frame with a FLAG epitope, within a lentiviral expression
vector. The resulting construct generates a protein lacking
the C-terminal 49 aminoacids, still retaining its biological
activity (19). Endogenous versus exogenous Sox6 can be
distinguished both at RNA (by RT–PCR; Figure 6A, right
panel) and at protein level (Figure 6B, right panel, and
‘Materials and Methods’ section).
In both K562 and Human Cord Blood (HCB) in vitro-
derived erythoblasts, the overexpression of the exogenous
Sox6 gene is mirrored by a dramatic reduction of both the
endogenous Sox6 transcript and protein (Figure 6A and
B, left panels), suggesting that high levels of Sox6 indeed
strongly repress the transcription of the endogenous gene.
To test whether this repression is associated to direct
in-vivo binding of the Sox6FLAG protein on the  775/
 759 motif within the Sox6 promoter, we performed chro-
matin immunoprecipitation (ChIP) on K562 cells
transduced with either the construct overexpressing the
Sox6FLAG protein or the corresponding empty vector
(K562-S6 and K562, respectively, in Figure 6C). The
anti-FLAG antibody was used to detect the exogenous
Sox6. As shown in Figure 6C, the anti-FLAG antibody
efﬁciently immunoprecipitates the Sox6 double site region
in cells expressing the exogenous Sox6FLAG protein (lane
6). The same sequence is not immunoprecipitated by the
same anti-FLAG antibody when chromatin from K562
cells transduced with the empty vector (lane 5) is used.
As a further negative controls, normal Rabbit-IgG fail
to immunoprecipitate the Sox6 promoter region in both
K562-S6 and empty vector-K562 chromatin samples
(lanes 3 4) and primers designed on the GAPDH gene
(lower gel) give no ampliﬁcation on the same immunopre-
cipitated samples as above. Real Time PCR quantiﬁcation
of Immunoprecipitated bands demonstrates that the
Sox6FLAG binding on the Sox6 promoter region is
stronger than that observed for the cyclin D1 promoter,
a known in-vivo target of Sox6 in insulinoma INS-1E and
NIH-3T3 cells (25), and thus used as positive control
(Figure 6C, lower panel).
Together, these data conﬁrm that Sox6 is indeed able to
repress its own transcription, possibly by direct binding
in vivo to its own promoter.
This observation prompted us to address in more detail
the chromatin dynamics of this region upon Sox6
overexpression (mimicking the accumulation of Sox6
during erythroid differentiation), by performing an
in vivo Restriction Enzyme Accessibility Assay. To this
end we exploited the presence of a PstI site 200nt
upstream to the double Sox6 consensus. As shown in
Figure 6D, in K562 cells infected with the empty vector,
this region is accessible to PstI cut, to an extent expected
for an intermediate hypersensitive site (22). In the presence
of high concentrations of Sox6 PstI is unable to access its
target site, conﬁrming that Sox6 binding to its target
sequences correlates with a ‘closed’ status of this region.
As a control, in both conditions (i.e. either basal level of or
high level of Sox6) a PstI site within the Gata-1 gene
results equally accessible in both conditions.
Sox6 binds to the conserved double consensus in vivo in
murine bone marrow erythroid cells
To conﬁrm the above observations in vivo, we moved to
primary mouse Bone Marrow cells.
ChIP carried out with an anti-Sox6 antibody conﬁrmed
the ability of Sox6 to bind to the mouse conserved Sox6
double element (Figure 7A). To reﬁne our analysis we then
FACS sorted from mouse Bone Marrow two cell popula-
tions: the CD71
+TER119
+ cells (R2), representing eryth-
roid progenitors, and cells negative for both markers (R1),
representing more immature cells (Figure 7B). ChIP on
chromatins from these populations reveals that Sox6 is
indeed able to bind to its consensus in erythroid cells
(R2) while it does not bind to the same sequence in
CD71
 TER119
  cells. Of note, Sox6 is already expressed
at low levels in the more immature cells (Figure 1D) but it
binds to its consensus only in more mature cells
(CD71
+TER119
+ cells), where it is present at high
concentration.
Since Sox6 can mediate transcriptional repression by
recruiting HDAC1 [as on the CycD promoter; (25)], we
tested whether HDAC1 was recruited on the Sox6 consen-
sus. Figure 7C shows that the binding of Sox6 to its
promoter is not associated with HDAC1 recruitment,
Figure 5. Continued
erythroblasts obtained from CD34
+ cells puriﬁed from either Peripheral Blood (left panels) or Cord Blood (right panels) were nucleofected with the
1116-S6wt and 1116-S6mut constructs at Days 8 and 12 of the cultures, in the presence of a Renilla-expressing plasmid to normalize for relative
transfection efﬁciencies. Upper panels: RealTime PCR assessing the expression level of the endogenous Sox6 (relative to GAPDH). Middle panels:
Luciferase activity driven by the 1116-S6wt element; Lower panels: Luciferase activity driven by the 1116-S6mut element at the same days (no
statistical signiﬁcant differences were found). Luciferase activity is given in arbitrary units. (D) The activity of the 1116-S6mut is higher than that of
the 1116-S6wt construct at late phases of erythroid differentiation (Day 12) when data from Peripheral and Cord Blood cells are plotted together
(normalized on Renilla expression). (E) ChIP demonstrates that at Day 12 SOX6 is indeed bound to its promoter. IgG antibodies were used as a
control. (F) A 234-nt fragment (either the WT or the mutated Sox6 double site) was cloned upstream to a highly active Gata-1-derived erythroid
cassette (pe construct). (G) All constructs were cotransfected in K562 cells together with increasing amounts (from 0.2 to 1.6mg) of a Sox6 expressing
plasmid. The pe+WT construct is repressed in a dose dependent manner by the addition of the cotransfected Sox6 expressing plasmid (black bars,
columns 7, 11, 15), while the corresponding mutated element, pe+MUT, is not (columns 8, 12, 16). A Sox4 expressing plasmid (at the highest
concentration of 1.6mg used for Sox6) fails to repress pe+WT, suggesting a Sox6 highly speciﬁc effect (lane 19). Sox6-FLAG and Sox4-FLAG
expressing plasmids produce comparable amounts of protein, as demonstrated by using the anti-FLAG antibody in the western blot on the right
(1.6mg of transfected plasmids, extracts from 5 10
5 transfected cells per lane).
496 Nucleic Acids Research, 2011,Vol. 39,No. 2Figure 6. Overexpression of exogenous Sox6 represses the endogenous Sox6 transcription. (A) Semiquantitative RT–PCR on cDNA from K562 and
HCB-derived progenitors cells transduced with either the Sox6 overexpressing vector or the corresponding empty vector. GAPDH was used to
normalize for cDNAs loading. The number of ampliﬁcation cycles used for each set of primers is indicated on the right of the ﬁgure. In Real Time
quantiﬁcation, the endogenous Sox6 transcript—in K562 and HCB cells overexpressing the Sox6FLAG protein—was scored as undetectable (not
shown). Right panel: primers combinations used to discriminate between endogenous versus exogenous Sox6 transcript. (B) Western blot analysis.
Nuclear extracts from 7 10
5 cells were loaded in each lane. Right panel: antibodies used to discriminate between endogenous versus exogenous Sox6
protein: the anti-FLAG antibody detects exogenous SOX6, while the endogenous protein is revealed by anti-SOX6 antibody raised again the
C-terminal portion of the protein, absent in the exogenous protein. The anti c1/c2 hnRNP antibody was used to normalize for protein loading.
(C) ChIP experiments. The anti-FLAG or rabbit IgG antibodies were used to immunoprecipitate chromatin from either K562 (transduced with the
empty vector) or K562 overexpressing Sox6FLAG (K562-S6) cells. Lanes 1 and 2: input chromatins. Lanes 3 and 4: normal rabbit IgG. Lane 5 and
6: anti-FLAG antibody. Lane 7: water. Upper gel: Sox6 promoter region. Lower gel: GAPDH genomic locus was used as a negative control. Lower
panel: Real Time quantiﬁcation of the Sox6 promoter enrichment in chromatin immunoprecipitated with the anti-FLAG antibody. GAPDH and
SOX4: negative control loci, cyclin D1: positive control. Real Time analysis was performed twice in triplicate. (D) Restriction enzyme accessibility
assay. Schematic representation (not in scale) of the position of the PstI endonuclease restriction site relative to the Sox6 binding sites within the
Sox6 promoter. Grey arrows indicate primers used to amplify the uncut copies of this region. In presence of low Sox6 level, PstI accesses the Sox6
promoter region (30% of cut copies, with P-value <0.0005) while in the presence of high Sox6 level it does not. A PstI recognition site within the
human GATA1 promoter is used as a positive control.
Nucleic AcidsResearch, 2011, Vol.39,No. 2 497suggesting that the repression on this element likely relies
on different molecular mechanisms.
To get insight into the chromatin conformation of this
region in primary cells we tested the chromatin accessibil-
ity of this region by looking at the presence of histone
modiﬁcations generally associated to either transcription-
ally active (H3K4me1) or transcriptionally repressed
(H3K27me3) chromatin (26). As shown in Figure 7D, in
the more immature cell population where the level of Sox6
is very low (see Figure 1D), the double Sox6 region is
Immunoprecipitated by the anti H3K4me1 but not by
the anti H3K27me3 antibody. In the more mature popu-
lation, in correspondence with the higher Sox6 concentra-
tion, a signiﬁcant enrichment in H3K27me3-modiﬁed
chromatin is observed together with H3K4me1 enrich-
ment on the double Sox6 consensus region. These data
are in agreement with the hypothesis that in the presence
of high Sox6 concentrations this region is involved in the
establishment of a repressed chromatin domain.
DISCUSSION
Sox6 plays critical roles in determining cell fate and dif-
ferentiation in different systems, including erythropoiesis;
however, the molecular mechanisms underlying its
function are very poorly understood. In particular,
despite its profound effect on red cell survival, prolifer-
ation and differentiation (11), the only Sox6 target known
in erythropoietic cells is the 36nt sequence within the
mouse ey-globin promoter (13). The direct binding of
Sox6 to this sequence has been proposed to repress
ey-globin gene expression in adult erythropoietic cells,
thus suggesting the Sox6 requirement for proper
embryonic-adult globin switching to occur. The ey site is
Figure 7. Sox6 binds the murine homologous Sox6 consensus region in bone marrow erythroid cells. (A) ChIP experiments. The anti-Sox6, rabbit
IgG, and the unrelated anti-Brn3 antibodies were used to immunoprecipitate chromatin from mouse total bone marrow. Upper gel: double Sox6
consensus region. Lower gel: region within the Sox6 exon 16, used as a negative control. (B) FACS analysis and sorting. Two cells populations were
sorted from murine bone marrow: erythroid CD71
+Ter119
+ (R2) and CD71
 Ter119
  (R1). (C) Chromatins from R1 and R2 cells populations were
immunoprecipitated using rabbit IgG, anti-Sox6 and anti-HDAC1 antibodies. (D) The same chromatins were immunoprecipitated using rabbit IgG
and anti-H3K4me1 (left) and anti-H3K27me3 (right) antibodies.
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orientation, spaced by 8nt. The prevalence of paired
consensi on the few known Sox6 target genes (1–3),
suggests that two sites are likely required for Sox6
function, although very little is known about their
relative conﬁguration and their spacing.
In the attempt to uncover new potential Sox6 targets in
erythroid cells, we undertook a genome-wide search of
evolutionarily conserved double Sox6 binding sites,
taking as a model the Sox6 consensus lying within the
mouse ey-globin gene promoter. By combining the bio-
informatic search with a data set of genes differentially
expressed during erythoid differentiation, we identiﬁed
seven potential targets of Sox6 regulation (Figure 2D),
the Sox6 gene itself included.
The double Sox6 binding site mapping within the
proximal promoter of the human Sox6 gene itself is
composed, according to the ‘paired sites module’ often
observed in Sox6 binding sites, by two sites in opposite
orientation and identical in their sequence (50AACAAA
G30 and 50CTTTGTT30, respectively), spaced by 3nt. As
in the case of the Sox6 sites on the ey-globin promoter, the
newly identiﬁed Sox6 target site studied in this article is
repressed by Sox6 binding (see below). In recent literature,
Sox6 has been proposed to work as a repressor, through
interactions with a variety of partner factors, in several cell
types (13,25,27,28). On the other hand, Sox6, together
with the highly related Sox5 and Sox9 genes, was origin-
ally identiﬁed as a master gene in chondrogenic differen-
tiation, where this ‘Sox trio’ activates the expression of
chondrogenic speciﬁc genes, such as type II collagen
(Col2a1), aggrecan (Agc), cartilage link protein (Crtl1)
and matrilin (3,4,29,30). On these targets, Sox5, Sox6
and Sox9 are thought to secure each other to their
binding sites to activate transcription (note that, while
Sox6 and Sox5 do not have a transactivation domain,
Sox9 possesses it, thus working as a typical transcription
factor) (31). Altogether, these data suggest that inter-
actions with various protein partners and/or different
DNA arrangements of Sox6 target sites might underlie
the different transcriptional outputs observed (activation
or repression) in different systems. The repression of Sox6
on the Sox6 promoter does not seem to be mediated by
HDAC1 recruitment, as shown in Figure 7C. The obser-
vation of different histone modiﬁcations and of a varied
accessibility (Figures 6C and 7) on the double Sox6 con-
sensus region in vivo suggests the differential recruitment
of chromatin remodelling/histones-modifying factors in
cells at different degrees of erythroid differentiation.
Sox6 downregulates its own expression by direct binding
to an upstream negative element
The Sox6 gene structure is extremely complex, as it
involves different promoters and possibly enhancers
which are spread over hundreds of kilobases (8,9), and it
is quite likely that the expression of Sox6 in different
tissues and during development relies for its active/
negative regulation on multiple regulatory elements, so
far poorly characterized. Our results identify a double
Sox6 consensus binding site, located  775/ 759nt
upstream to one of the identiﬁed human Sox6 transcrip-
tional start sites (24); we propose that this site may par-
ticipate in the regulation of Sox6 expression during
erythroid maturation, by negatively modulating the tran-
scription from this promoter in erythroid cells. Indeed,
this site is directly bound by Sox6 both in vitro
(Figure 4; EMSA experiments) and in vivo (ChIP,
Figures 5E and 6C) and is required for Sox6-dependent
repression of reporter constructs in both K562 (and P19)
cells lines as well as in erythroblasts obtained from
primary CD34
+ cells from Peripheral and Cord Blood
(Figures 5B and C). The binding of exogenous Sox6 to
the double binding site within the Sox6 promoter
(Figure 6C) correlates with a change in chromatin acces-
sibility (Figure 6D), further indicating that the binding of
Sox6 to this region is indeed relevant to this repression.
According to this hypothesis, the increase of Sox6 in bone
marrow erythroid cells is accompanied by the appearance
of repressive histone marks in this region (Figure 7D).
Moreover, overexpression of exogenous Sox6 causes a
strong downregulation of the endogenous Sox6 transcript
and protein, both in K562 cells and in primary erythroid
cultures (Figure 6A and B).
Recently, Ikeda et al. (32) identiﬁed an alternative Sox6
promoter active in embryonic tissues and located nearly
128-kb upstream to the sequence investigated in the
present study. The corresponding transcript is far less
abundant in K562 cells than the main transcript studied
in this paper, and decreases, as the main transcript, upon
Sox6 overexpression (as shown in Figure 6A, where the
primers used in RT–PCR detect both transcripts).
Whether this transcript is also directly repressed by Sox6
in erythroid cells is presently not known.
Sox6 autoregulation during erythroid differentiation
Genetic circuits of autoregulation of key transcription
factors, affecting the rate of their synthesis by inﬂuencing
the rate of transcription (either by autoactivation or
autorepression), are known to govern many processes
involving progressive commitment of pluripotent progeni-
tors into lineage-restricted cells (33,34) where they are
thought to reinforce cell-fate decisions.
Having shown that Sox6 overexpression is able to
repress endogenous Sox6 transcription, we asked
whether the kynetics of Sox6 expression during normal
erythropoiesis may reﬂect possible Sox6 roles in
autoregulation. Our experiments show that, following a
sharp increase of Sox6 expression during the transition
from undifferentiated progenitors to early erythroblasts,
Sox6 is progressively downregulated during late stages of
erythropoiesis (Figure 1). This observation is consistent
with a negative modulatory role of Sox6 on its own
promoter, although it is possible that changes in other
transcription factors (dependent or independent from
Sox6) as well as other sequences within the Sox6 locus
might also contribute to the regulation of Sox6
transcription.
Many examples of autoregulation are known within the
hematopoietic system: Gata-1 is expressed at low levels in
multipotent progenitors, but becomes abundant in
Nucleic AcidsResearch, 2011, Vol.39,No. 2 499committed erythroid precursors where its transcription is
sustained by a positive feedback loop (35,36 and refer-
ences therein). Later on, Gata-1 expression declines at
advanced stages of erythroid differentiation (36,37).
Interestingly, the initial upregulation of Gata-1 in eryth-
roid differentiation is also linked to repression of another
member of the family, Gata-2, which predominates in
early progenitors, and may bind to a subset of
Gata1-binding sites, often eliciting opposite effects to
those of Gata-1 (38,39). In this regard, it would be of
great interest to test whether other Sox family members
can share common targets with Sox6, either at different
stages of erythroid differentiation or in other tissues in
which Sox6 is important for cell differentiation. A candi-
date for such a role in hematopoiesis is Sox4, which is
expressed in early progenitors prior to Sox6 and is pro-
gressively repressed during differentiation (unpublished
results), with a kinetics opposite to that of Sox6 induction.
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